Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/4TZ stock hub

FRA/4TZ has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/4TZis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

778.3M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/4TZFRA/4TZ

—

Loading chart…

In the news

Latest news · FRA/4TZ

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-42.6

P25 n/aP50 n/aP75 n/a

ROIC-28.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/4TZ market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

140

Groups with data

Currency

USD

Showing 140 of 140 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	104
Employees Change	-6%
Employees Change Percent	-5.36
Enterprise value	EUR 544.5M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 778.3M
Price	EUR 7.39
Price currency	EUR
Sic	2836
Symbol	fra/4TZ
Website	https://www.oricpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.07%
EV Earnings	-4.64x
EV/FCF	-5.65x
FCF yield	-12.39%
P/B ratio	2.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	EUR -117.3M
Profit Per Employee	EUR -1.1M
ROA	-27.57
Roa5y	-24.85
ROCE	-35.78
ROE	-42.57
Roe5y	-41.01
ROIC	-28.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	77.67%
Cagr3y	18.14%
Cagr5y	-17.81%

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	EUR 378.8M
Cash	EUR 244.5M
Current Assets	EUR 246.1M
Current Liabilities	EUR 15.1M
Debt	EUR 5.8M
Debt Equity	EUR 0.02
Debt FCF	EUR -0.06
Equity	EUR 360.4M
Liabilities	EUR 18.4M
Long Term Assets	EUR 132.7M
Long Term Liabilities	EUR 3.3M
Net Cash	EUR 238.7M
Net Cash By Market Cap	EUR 30.67
Net Cash Growth	41.12%
Net Debt Equity	EUR -0.66
Tangible Book Value	EUR 360.4M
Tangible Book Value Per Share	EUR 3.48

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	16.33
Net Working Capital	EUR -5.4M
Quick ratio	15.86
Working Capital	EUR 236.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-36.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	77.6%
200-day SMA	9.27
3Y total return	64.91%
50-day SMA	9.31
50-day SMA vs 200-day SMA	50over200
5Y total return	-62.5%
All Time High	33.65
All Time High Change	-78.04%
All Time High Date	2020-06-08
All Time Low	2.38
All Time Low Change	210.42%
All Time Low Date	2022-11-07
ATR	0.4
Ch YTD	7.07
High	7.39
High52	13.3
High52 Date	2025-10-07
High52ch	-44.45%
Low	7.39
Low52	4.12
Low52 Date	2025-05-19
Low52ch	79.32%
Ma50ch	-20.68%
Price vs 200-day SMA	-20.28%
RSI	37.96
RSI Monthly	46.63
RSI Weekly	41.9
Sharpe ratio	0.92x
Sortino ratio	1.46
Total Return	-36.45%
Tr YTD	7.07
Tr1m	-0.78%
Tr1w	-11.31%
Tr3m	-14.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -130M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	70,726,407%
Shares Insiders	1.23%
Shares Institutions	87.91%
Shares Qo Q	2.81%
Shares Yo Y	36.45%
Short Ratio	11.06

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -118.5M
Average Volume	89.5x
Bv Per Share	3.48
CAPEX	EUR -283,607
Ch1m	-0.78
Ch1w	-11.31
Ch1y	77.6
Ch3m	-14.09
Ch3y	64.91
Ch5y	-62.5
Ch6m	-30.3
Change	-1.65%
Change From Open	-0.03
Close	7.51
Days Gap	-1.6
Depreciation Amortization	1,007,378.9
Earnings Date	2026-08-12
EBIT	EUR -130M
EBITDA	EUR -129M
EPS	EUR -1.22
F Score	2
FCF	EUR -96.4M
FCF EV Yield	-17.71x
Financing CF	265,734,649
Fiscal Year End	December
Founded	2,014
Investing CF	-163,447,889
Is Primary Listing	0
Last Earnings Date	2026-02-18
Last Report Date	2026-03-31
Ma150	9.42
Ma150ch	-21.55%
Ma20	8.45
Ma20ch	-12.56%
Net CF	6,124,873
Next Earnings Date	2026-08-12
Open	7.39
Ppne	1,820,574.4
Price Date	2026-05-08
Ptbv Ratio	2.16
Relative Volume	4.11x
Share Based Comp	22,012,941
Tr6m	-30.3%
Volume	0

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/4TZ pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/4TZ stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/4TZ?

Insider, institutional, and short-interest positioning.

Institutional ownership

+87.9%

Share of float held by funds and institutions

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/4TZ momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.0

Neutral momentum band

Price vs 200-day MA

-20.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.92

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/4TZ

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/4TZ stock rating?

fra/4TZ is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/4TZ analysis?

The full report lives at /stocks/fra/4TZ/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/4TZ?

The latest report frames fra/4TZ around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/4TZ page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.